Navigation Links
Oncothyreon reports second quarter 2009 financial results

SEATTLE, Aug. 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) today reported a net loss of $6.3 million, or $0.30 per basic and diluted share, for the three months ended June 30, 2009, compared with a net loss of $4.9 million, or $0.25 per basic and diluted share, for the comparable period in 2008. Oncothyreon recorded a non-cash charge of $2.5 million in the three months ended June 30, 2009 for the change in the fair value of warrants issued in connection with its May 2009 securities offering. The increase in net loss for the three-month period was primarily the result of this non-cash charge and a decrease in revenue described below, partially offset by decreased operating expenses.

Oncothyreon reported a net loss of $8.8 million, or $0.43 per basic and diluted share, for the six months ended June 30, 2009, compared with a net loss of $10.1 million, or $0.51 per basic and diluted share, for the comparable period in 2008. The decrease in net loss for the six-month period was primarily the result of the transfer of manufacturing activities for Stimuvax(R) to Merck KGaA in December 2008, which resulted in a decrease of combined research and development and manufacturing expenses partially offset by a decrease in both contract manufacturing and licensing revenue from collaborative agreements and the non-cash charge discussed above.

Total revenue was $31,000 and $35,000, respectively, for the three and six months ended June 30, 2009, compared to $1.2 million and $3.2 million for the same periods in 2008. The decrease in revenue was primarily the result of the transfer of manufacturing of Stimuvax to Merck KGaA in December 2008.

Total expenses for the three and six months ended June 30, 2009 were $6.4 million and $8.8 million respectively, compared with $6.1 million and $13.2 million for the comparable periods in 2008. Combined research and development and manufacturing expenses decreased to $2.0 million for the three months ended June 30, 2009 from $3.4 million for the three months ended June 30, 2008, and to $2.7 million from $7.8 million for the six month periods, primarily as the result of the cessation of manufacturing activities for Stimuvax and the transfer of our Edmonton, Alberta facility to Merck KGaA. General and administrative expenses decreased to $1.7 million in the three months ended June 30, 2009 from $2.7 million in the three months ended June 30, 2008. General and administrative expenses decreased to $3.5 million in the first six months of 2009 from $5.4 million in the first six months of 2008, primarily as a result of expenses in 2008 related to Oncothyreon's reincorporation in the United States and of fewer personnel in 2009. Decreases in operating expenses were offset by the $2.5 million non-cash charge discussed earlier.

As of June 30, 2009, Oncothyreon's cash and cash equivalents were $22.7 million, compared to $19.2 million at the end of 2008, an increase of $3.5 million, or 18.2 percent. Major contributors to the net change included net proceeds of $10.1 million from the sale of 3,878,993 shares of Oncothyreon's common stock and warrants to purchase 2,909,244 shares of Oncothyreon's common stock, offset by $6.5 million used in operations in the first six months of 2009.

On August 7, 2009, subsequent to the period covered by this release, Oncothyreon closed the sale of approximately 2.28 million shares of its common stock and warrants to purchase approximately 684,000 shares of its common stock for net proceeds of approximately $14 million.

Financial Guidance

Oncothyreon believes the following financial guidance to be correct as of the date provided. Oncothyreon is providing this guidance as a convenience to investors and assumes no obligation to update it.

Expenses in 2009 are expected to be substantially less than in 2008, primarily as a result of transferring manufacturing and process development activities for Stimuvax to Merck KGaA and of the previously announced plan to restrict development activities to PX-478 and PX-866. Oncothyreon currently expects cash used in operations in 2009 to be approximately $12 million.

    Oncothyreon Highlights for 2009

    Oncothyreon's corporate highlights for the year 2009 to date include the

    -   Expansion of the Phase 3 development program for Stimuvax with the
        initiation of the STRIDE trial in hormone receptor-positive, locally
        advanced, recurrent or metastatic breast cancer by Oncothyreon's
        partner Merck KGaA. Stimuvax is also being studied in the Phase 3
        START trial in non-small cell lung cancer (NSCLC).
    -   Presentation of long-term data for Stimuvax in NSCLC at the
        International Association for the Study of Lung Cancer's 13th World
        Conference on Lung Cancer. The data involved 16 patients who received
        treatment with Stimuvax for between 2 and 8.2 years as part of the
        Phase 2b trial in patients with stage IIIb/IV NSCLC. As of the time
        of data analysis in April 2009, 10 of the 16 studied patients were
        alive without evidence of disease progression, of whom eight
        continued to receive therapy with Stimuvax after 6.3 to 8.2 years.
        The remaining two living patients discontinued Stimuvax therapy after
        2.4 and 5.8 years, respectively, and were without evidence of disease
    -   Presentation of preliminary results from the Phase 1 trial of PX-866,
        an inhibitor of PI-3 kinase, at the American Society of Clinical
        Oncology. The data demonstrated inhibition of PI-3 kinase activity at
        low doses, as well as stabilization of disease in six of 24 patients
        with previously progressive disease in the early dose cohorts in this
        ongoing dose escalation trial.
    -   Improvement of Oncothyreon's financial position with the completion
        of two offerings of units consisting of shares of common stock and
        warrants, which generated combined net proceeds to Oncothyreon of
        approximately $24 million.
    -   Strengthening of Oncothyreon's senior management team with the
        addition of Scott Peterson, Ph.D, as Vice President, Research and
        Development, and Diana Hausman, M.D., as Vice President, Clinical

Conference Call and Webcast

Oncothyreon's management will discuss the Company's second quarter 2009 financial results and provide a business update during a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today, Wednesday, August 12, 2009. To listen to a webcast of the discussion, visit

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of our current results and future prospects, this release may contain statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include our expectations regarding future expenses, clinical development activities and the use and adequacy of cash resources.

Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing our product candidates, the adequacy of financing and cash reserves on hand, changes in general accounting policies, general economic factors, achievement of the results we anticipate from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

Additional Information

Additional information relating to Oncothyreon can be found on U.S. EDGAR at and on SEDAR at

                               Oncothyreon Inc.

     Consolidated Statements of Operations and Other Comprehensive Loss Data
                   (in thousands except per share amounts)

                                      Three Months Ended    Six Months Ended
                                             June 30             June 30
                                      ------------------  ------------------
                                          2009      2008      2009      2008
                                      --------  --------  --------  --------
      Contract manufacturing.........        -       802         -     2,520
      Licensing revenue from
       collaborative agreements......        4       350         8       652
      Licensing, royalties and
       other revenue.................       27         -        27         -
                                      --------  --------  --------  --------
                                            31     1,152        35     3,172
                                      --------  --------  --------  --------

      Research and development.......    1,995     2,726     2,675     5,034
      Manufacturing..................        -       646         -     2,726
      General and administrative.....    1,745     2,661     3,496     5,364
      Amortization...................       67       103       132       206
      Investment and other income....       54       (68)       34      (128)
      Change in fair value of
       warrant liability.............    2,502         -     2,502         -
                                      --------  --------  --------  --------
                                         6,363     6,068     8,839    13,202
                                      --------  --------  --------  --------
    Net loss.........................   (6,332)   (4,916)   (8,804)  (10,030)
    Other comprehensive income
     (loss)..........................        -        72         -       (31)
                                      --------  --------  --------  --------
    Comprehensive net loss........... $ (6,332) $ (4,844) $ (8,804) $(10,061)
                                      --------  --------  --------  --------
                                      --------  --------  --------  --------
    Basic and diluted loss per
     share........................... $  (0.30) $  (0.25) $  (0.43) $  (0.51)
                                      --------  --------  --------  --------
    Weighted average number of
     common shares outstanding.......   20,984    19.492    20,243    19.489
                                      --------  --------  --------  --------
                                      --------  --------  --------  --------

                               Oncothyreon Inc.

                       Consolidated Balance Sheets Data
                               (in thousands)

                                            June 30, 2009  December 31, 2008

    Cash, cash equivalents and short term
     investments...............................  $ 22,706           $ 19,166
    Total assets...............................  $ 28,110           $ 24,971
    Total long-term liabilities................  $  7,105           $    393
    Stockholders' equity.......................  $ 18,549           $ 20,717
    Common shares outstanding..................    23,371             19,492

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):